Tag: Chugai Pharmaceutical

March 17, 2022 Off

AstraZeneca Reaches Settlement Agreement Resolving Patent Litigation Related to Ultomiris

Alexion, AstraZeneca’s Rare Disease group, has entered into a settlement agreement with Chugai Pharmaceutical Co., Ltd. (Chugai), resolving all patent disputes between the two companies related to Ultomiris (ravulizumab).

April 24, 2020 Off

Positive outcome from study for Chugai’s satralizumab

By BusinessWire

Satralizumab monotherapy significantly reduced risk of relapse in patients with NMOSD, following a previous positive study where satralizumab was added to baseline immunosuppressant therapy.